Overview
Methemoglobinemia induced by drugs occurs when medications interfere with normal hemoglobin function, reducing oxygen-carrying capacity by converting ferric (Fe3+) to ferrous (Fe2+) iron in hemoglobin, leading to tissue hypoxia 1.Diagnosis
Elevated methemoglobin levels (>2%) on co-oximetry 1.
Clinical symptoms including cyanosis, dyspnea, confusion, and fatigue 1.
Exclusion of other causes of cyanosis through history and physical examination 1.Management
First-line treatment: Administration of methylene blue (1-2 mg/kg intravenously, repeated if necessary) 1.
Adjunctive measures: Exchange transfusion in severe cases or refractory methemoglobinemia 1.
Supportive care: Oxygen therapy, monitoring of vital signs, and addressing underlying causes 1.Special Populations
Pregnancy: Limited data; management similar to non-pregnant adults with close monitoring 1.
Pediatrics: Dose adjustment for methylene blue may be required (0.2 mg/kg IV) and close observation for adverse effects 1.
Elderly: Increased vigilance for complications due to comorbidities; individualized treatment plans 1.
Comorbidities: Consider impact on oxygen delivery and clearance; tailor treatment based on coexisting conditions 1.Key Recommendations
Identify and discontinue the offending drug promptly to prevent further methemoglobin formation (Evidence: Expert opinion) 1.
Use methylene blue as the primary treatment for drug-induced methemoglobinemia (Evidence: Expert opinion) 1.
Monitor patients closely for response and potential side effects, especially in vulnerable populations like pediatric and elderly patients (Evidence: Expert opinion) 1.References
1 Ayala A, F-Lobato M, Machado A. Malic enzyme levels are increased by the activation of NADPH-consuming pathways: detoxification processes. FEBS letters 1986. link80657-3)